MYCN-targeting vaccines and immunotherapeutics

References

• Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, Nau MM, Witte ON, Toran-Allerand D, Gee CE. Differential expression of myc family genes during murine development. In: Nature 1986; 319(6056):780-3; PMID:2419762; http://dx.doi.org/10.1038/319780a0
   PubMed Web of Science ®Google Scholar
• Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. In: Cancer Cell 2013; 24(1):75-89; PMID:23792191
   PubMed Web of Science ®Google Scholar
• Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. In: Cancer Cell 2014; 26(3):414-27; PMID:25175806
   PubMed Web of Science ®Google Scholar
• Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N, Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. In: Cancer Cell 2009; 15(1):67-78; PMID:19111882
   PubMed Web of Science ®Google Scholar
• Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. In: Oncotarget 2013; 4(11):2080-95; PMID:24231268
   PubMed Web of Science ®Google Scholar
• Henssen AG, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, et al. Targeting MYCN-driven transcription by BET-bromodomain inhibition. In: Clin Cancer Res 2015; PMID:26631615
   PubMed Web of Science ®Google Scholar
• Cheung Nai-Kong V, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. In: Nat Rev Cancer 2013; 13(6):397-411; PMID:23702928
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F. Long-term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. In: BMC Cancer 2011b; 11:21; http://dx.doi.org/10.1186/1471-2407-11-21
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. In: N Eng J Med 2010; 363(14):1324-34; http://dx.doi.org/10.1056/NEJMoa0911123
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. In: Blood 2011; 118(23):6050-6; PMID:21984804
   PubMed Web of Science ®Google Scholar
• Simon T, Berthold F, Borkhardt A, Kremens B, Carolis B de, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. In: Pediatric Blood Cancer 2011a; 56(4):578-83
   PubMed Web of Science ®Google Scholar
• Versteeg R, van der Minne C, Plomp A, Sijts A, van Leeuwen A, Schrier P. N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. In: Mol Cell Biol 1990; 10(10):5416-23; PMID:2204814; http://dx.doi.org/10.1128/MCB.10.10.5416
   PubMed Web of Science ®Google Scholar
• Song L, Ara T, Wu Hong-wei, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. In: J Clin Invest 2007; 117(9):2702-12; PMID:17710228; http://dx.doi.org/10.1172/JCI30751
   PubMed Web of Science ®Google Scholar
• Song L, Asgharzadeh S, Salo J, Engell K, Wu Hong-wei, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. In: J Clin Invest 2009; 119(6):1524-36; PMID:19411762; http://dx.doi.org/10.1172/JCI37869
   PubMed Web of Science ®Google Scholar
• Sarkar AK, Nuchtern JG. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. In: Cancer Res 2000; 60(7):1908-13.; PMID:10766179
   PubMed Web of Science ®Google Scholar
• Pistoia V, Morandi F, Pezzolo A, Raffaghello L; Prigione I. MYCN: from oncoprotein to tumor-associated antigen. In: Frontiers Oncol 2012; 2:174
   PubMedGoogle Scholar
• Himoudi N, Yan M, Papanastasiou A, Anderson J. MYCN as a target for cancer immunotherapy. In: Cancer Immunol Immunotherapy 2008; 57(5):693-700
   PubMed Web of Science ®Google Scholar
• Stermann A, Huebener N, Seidel D, Fest S, Eschenburg G, Stauder M, Schramm A, Eggert A, Lode HN. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. In: Cancer Immunol Immunotherapy 2015; 64(10):1215-27; http://dx.doi.org/10.1007/s00262-015-1733-1
   PubMed Web of Science ®Google Scholar
• Berger E, Soldati R, Huebener N, Hohn O; Stermann A, Durmus T, Lobitz S, Zenclussen AC, Christiansen H, Lode HN, et al. Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma. In: Cancer Letters 2013; 331(2):167-73; PMID:23337288
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Parodi A, Lavieri R, Kalli F, Ferrera F, Tagliamacco A, Guastalla A, Lamperti MG, Giacomini M, Filaci G. Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. In: Hum Vaccines Immunotherapeutics 2015; 11(4):838-50
   PubMed Web of Science ®Google Scholar
• Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. In: Prostate 2009; 69(9):917-27; PMID:19267352
   PubMed Web of Science ®Google Scholar
• Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. In: Hum Vaccines Immunotherapeutics 2014; 10(11):3179-89
   PubMed Web of Science ®Google Scholar